verified SJR 0,969 · Q1 • database Scopus / SJR & Web of Science indexed

Germany · Springer Science and Busines...

workspace_premium Q1 — Pharmacology lock Subscription

Cancer Chemotherapy and Pharmacology

Cancer Chemotherapy and Pharmacology is a journal indexed in SJR in Pharmacology and Oncology with an H index of 127. It has a price of 3060 €. It has an SJR impact factor of 0,969 and it has a best quartile of Q1. It is published in English. It has an SJR impact factor of 0,969.

Cancer Chemotherapy and Pharmacology focuses its scope in these topics and keywords: cell, human, patients, kinase, combination, correlation, etoposide, highdose, oral, ovarian, ...

ISSN: 0344-5704

Publisher: Springer Science and Business Media Deutschland GmbH

Category: Pharmacology

Indexation: verifiedScopus / SJR verifiedWeb of Science

open_in_new Portal NPD menu_book Guidelines NPD

schedule CountryOfPapers database fields

SJR Impact Factor trending_up

0,969 Q1

H-index 127

Acceptance rate pie_chart

23% Selective

Source Acceptance_Rate

Time to publication hourglass_top

NPD

Field NPD

Publication cost (APC) payments

3.060 € Subscription

Non-OA path 0 €

Metrics

Scimago and CountryOfPapers database fields

Scopus / SJR Web of Science

SJR Impact

0,969

H-index

127

Docs (year)

128

Docs 3y

397

Total refs

4572

Cites 3y

1145

Citable 3y

392

Cites/Doc 2y

2.7

Ref/Doc

35.72

Immediate OA

3060 €

Embargoed OA

NPD

Non OA / Submission

0 €

shield Researcher voice

Name good journals. Call out predatory ones.

Share what peer review, fees, and timelines were really like. Praise fair editors. Flag APC traps, fake metrics, or spam solicitations — with facts from your submission.

Fair & fast peer review Clear APC / no surprise fees Suspected predatory Fake impact claims

rate_review Write an honest review

Researcher reviews

sentiment_dissatisfied No reviews yet — be the first to share an honest experience.

Publication speed *

Review quality *

Edition and editorial team *

Institutional email or ORCID * * Only to validate authenticity — identity is not shown publicly.

Best articles by citations

Amifostine does not reduce the toxicity of the fludarabine and cyclophosphamide regimen in patients with chronic lymphocytic leukemia

Two potential mechanisms of oxaliplatin-induced haemolytic anaemia in a single patient

BRCA1 transcriptional activity is enhanced by interactions between its AD1 domain and AhR

Bortezomib induces protective autophagy through AMP-activated protein kinase activation in cultured pancreatic and colorectal cancer cells

Bioavailability and pharmacokinetics of the cardioprotecting flavonoid 7-monohydroxyethylrutoside in mice

Biliary excretion of 17-(allylamino)-17-demethoxygeldanamycin (NSC 330507) and metabolites by Fischer 344 rats

Bi-weekly chemotherapy with cisplatin, epirubicin, folinic acid and 5-fluororacil continuous infusion plus g-csf in advanced gastric cancer: a multicentric phase II study

Bcl-2-mediated potentiation of neocarzinostatin-induced apoptosis: requirement for caspase-3, sulfhydryl groups, and cleavable Bcl-2

Arsenic trioxide induces apoptosis in cells of MOLT-4 and its daunorubicin-resistant cell line via depletion of intracellular glutathione, disruption of mitochondrial membrane potential and activation of caspase-3

Anthracycline analogs The past, present, and future

Anagrelide and imatinib mesylate combination therapy in patients with chronic myeloproliferative disorders

An orally active Amazonian plant extract (BIRM) inhibits prostate cancer growth and metastasis

SHOW MORE ARTICLES

An effective oral combination in advanced relapsed Hodgkin's disease prednisolone, etoposide, chlorambucil and CCNU

A multicenter phase II study of irinotecan (CPT-11) alternated with 5-fluorouracil and leucovorin as first-line treatment of patients with metastatic colorectal cancer

Alleviation of side effects induced by irinotecan hydrochloride (CPT-11) in rats by intravenous infusion

Acute effects of megestrol on the hypothalamic?pituitary?adrenal axis

Activity of docetaxel in paclitaxel-resistant ovarian cancer cells

A retrospective evaluation of the feasibility of intrapatient dose escalation as appropriate methodology for dose-ranging studies for combination cytotoxic regimens

A phase II trial of DA-125, a novel anthracycline, in advanced non-small-cell lung cancer

A phase I, open-label, randomized crossover study to assess the effect of dosing of the MEK 1/2 inhibitor Selumetinib (AZD6244; ARRY-142866) in the presence and absence of food in patients with advanced solid tumors

A phase I, dose escalation trial of ZD0473, a novel platinum analogue, in combination with gemcitabine

A phase I trial of weekly paclitaxel, 13- cis -retinoic acid, and interferon alpha in patients with prostate cancer and other advanced malignancies

A phase I study of ZD0473 combined with paclitaxel for the treatment of solid malignancies

A phase I study of 9-aminocamptothecin as a colloidal dispersion formulation given as a fortnightly 72-h infusion

FAQs

Cancer Chemotherapy and Pharmacology has an SJR of 0,969 (best quartile Q1) in the CountryOfPapers database.

Immediate OA APC is 3060 EUR. Non-OA / submission fee is 0 EUR.

The acceptance rate recorded for Cancer Chemotherapy and Pharmacology is 23%.

Cancer Chemotherapy and Pharmacology

Metrics

Name good journals. Call out predatory ones.

Researcher reviews

Best articles by citations

FAQs

What is the SJR of Cancer Chemotherapy and Pharmacology?

What is the APC / publication cost?

What is the acceptance rate?